Table 3.
Latent class growth analysis of four symptoms reported during childhood ALL therapy and association with ALL relapse
| Symptom Evaluation Time Point | |||||||
|---|---|---|---|---|---|---|---|
| N | Time 1 Median (IQR) | Time 2 Median (IQR) | Time 3 Median (IQR) | Time 4 Median (IQR) | Unadjusted HR (95% CI) | Adjusted1 HR (95% CI) | |
| Fatigue | |||||||
| Class 1 | 119 | 44.3 (38.4–48.9) | 42.9 (40.0–46.8) | 44.0 (40.3–47.7) | 44.5 (40.6–48.1) | Ref | Ref |
| Class 2 | 70 | 51.5 (45.7–57.2) | 55.1 (49.7–58.4) | 53.9 (49.9–59.1) | 56.0 (50.9–60.5) | 0.99 (0.39–2.51) | 1.69 (0.60–4.75) |
| Class 3 | 19 | 64.6 (58.4–68.8) | 67.7 (61.3–72.4) | 65.3 (62.8–71.4) | 64.0 (59.4–71.7) | 1.57 (0.46–5.38) | 2.78 (0.80–9.62) |
| Sleep | |||||||
| Class 1 | 79 | 1.9 (1.7–2.2) | 2.0 (1.7–2.2) | 2.0 (1.7–2.2) | 2.0 (1.6–2.2) | Ref | Ref |
| Class 2 | 111 | 2.9 (2.6–3.3) | 3.1 (2.6–3.3) | 2.9 (2.6–3.4) | 2.9 (2.5–3.3) | 3.58 (1.04–12.31) | 3.81 (1.03–14.06) |
| Class 3 | 24 | 3.7 (3.4–4.1) | 3.9 (3.7–4.4) | 4.0 (3.5–4.3) | 4.0 (3.7–4.5) | 3.62 (0.81–16.17) | 4.50 (0.75–26.82) |
| Pain | |||||||
| Class 1 | 43 | 0 (0–0) | 0 (0–0) | 0 (0–0) | 0 (0–0) | Ref | Ref |
| Class 2 | 92 | 2 (2–4) | 0 (0–2) | 0 (0–0) | 0 (0–0) | 6.24 (0.81–48.13) | 5.38 (0.65–44.26) |
| Class 3 | 79 | 2 (2–6) | 2 (0–4) | 2 (2–4) | 2 (2–4) | 4.81 (0.61–38.19) | 5.24 (0.62–44.18) |
| Nausea | |||||||
| Class 1 | 86 | 0 (0–1) | 0 (0–0) | 0 (0–1) | 0 (0–2) | Ref | Ref |
| Class 2 | 68 | 20 (4–33) | 7 (1–20) | 10 (0–20) | 1 (0–10) | 2.86 (0.88–9.25) | 3.49 (1.04–11.72) |
| Class 3 | 60 | 10 (0–48) | 28 (9–50) | 30 (14–50) | 25 (10–40) | 3.64 (1.10–12.02) | 7.46 (2.27–24.54) |
Acute lymphoblastic leukemia, ALL; interquartile range, IQR; hazard ratio, HR; confidence interval, CI
1
Model adjusted for age, gender, ethnicity, BMI z-score at diagnosis, diagnosis, and treatment risk group
*
Time points: end induction (time 1), delayed intensification day 1 (time 2), maintenance cycle 1 day 1 (time 3), maintenance cycle 2 day 1 (time 4)